DICE Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DICE research report →
Companywww.dicemolecules.com
DICE Therapeutics, Inc. , a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.
- CEO
- J. Kevin Judice
- IPO
- 2021
- Employees
- 71
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $2.27B
- P/E
- -22.94
- P/S
- 0.00
- P/B
- -9.99
- EV/EBITDA
- -21.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 56.07%
- ROIC
- -14.80%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-81,664,000 · -68.48%
- EPS
- $-2.07 · 47.06%
- Op Income
- $-88,221,000
- FCF YoY
- -66.36%
Performance & Tape
- 52W High
- $47.90
- 52W Low
- $15.08
- 50D MA
- $42.26
- 200D MA
- $34.24
- Beta
- 0.00
- Avg Volume
- 1.75M
Get TickerSpark's AI analysis on DICE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 9, 23 | RA CAPITAL MANAGEMENT, L.P. | sell | 21,250 |
| Aug 9, 23 | RA CAPITAL MANAGEMENT, L.P. | other | 786,407 |
| Aug 9, 23 | TETLOW SHARON | sell | 21,250 |
| Aug 9, 23 | TETLOW SHARON | sell | 49,841 |
| Aug 9, 23 | TETLOW SHARON | sell | 13,800 |
| Aug 9, 23 | Simson Jake | sell | 21,250 |
| Aug 9, 23 | Scopa James Paul | sell | 13,800 |
| Aug 9, 23 | Scopa James Paul | sell | 21,250 |
| Aug 9, 23 | Scopa James Paul | sell | 25,722 |
| Aug 9, 23 | Robertson Scott M. | sell | 56,920 |
Our DICE Coverage
We haven't published any research on DICE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DICE Report →